The biotech group pulled off a refinancing coup this month that sharply reduces its interest expense, yet the market’s immediate reaction has been anything but grateful. Ocugen completed a $130 million private placement of convertible notes due in 2034, netting approximately $112.6 million after costs. Of that haul, $32.7 million went straight to extinguishing a high-cost loan from Avenue Capital Group, replacing a 12.5% interest rate with a far more manageable 6.75%. The move stretches Ocugen’s cash runway into 2028, taking near-term financing pressure off the table.
But convertible debt carries an unwelcome sting for existing shareholders: the potential for future equity dilution. That fear has dogged the stock, which slid more than 26% over the past month to close at €1.18 on German exchanges. The shares now trade well below both their 50-day moving average of €1.57 and the 200-day line of €1.29. On the weekly close alone, the loss amounted to 5.3%, and a particularly sharp 21.4% drop followed the company’s first-quarter earnings miss.
The quarterly numbers painted a mixed picture. Revenue of $1.53 million beat analyst estimates, but the net loss of $0.06 per share came in modestly above consensus expectations. Operating expenses rose to $19.4 million from $16.0 million a year earlier, with research and development accounting for $11.3 million of that total. The widening burn underscores the cost of pushing a complex gene therapy pipeline toward registration.
On the clinical front, however, Ocugen delivered encouraging data that offered a counterbalance. At the Retina World Congress on May 14, the company presented results from the Phase 2 ArMaDa study of its modifier gene therapy candidate OCU410, targeting geographic atrophy secondary to dry age-related macular degeneration. The mid-dose cohort showed a 31% reduction in lesion growth at twelve months compared to the control arm — a figure that stacks up favorably against approved therapies, which have posted reductions of 15% and 22% in similar analyses.
Should investors sell immediately? Or is it worth buying Ocugen?
Other pipeline assets are also advancing. The liMeliGhT study for OCU400 in retinitis pigmentosa has completed enrollment of 140 participants, with top-line data expected early in 2027. Ocugen plans to submit a rolling biologics license application for OCU400 beginning in the third quarter of 2026, targeting completion by the second quarter of 2027 and potential approval by the end of that year. Meanwhile, the GARDian3 trial for Stargardt disease enrolled and dosed all 63 subjects ahead of schedule; an interim analysis of 24 patients is slated for the third quarter of 2026. For OCU410 itself, the company intends to align with regulators on a Phase 3 study design and launch the pivotal trial in the same quarter.
Analysts remain broadly upbeat despite the stock’s slide. Of the six covering the name, the average price target stands at $12.33, with a high of $22 and a low of $12. One analyst reiterated a buy rating in May, citing the strength of the gene therapy data. The wide gap between those targets and the current share price reflects the binary nature of biotech investing — everything hinges on whether the clinical successes can eventually overcome dilution concerns.
Technical indicators suggest the selling may have gone too far. The relative strength index has dipped to 25, placing the stock in oversold territory. With the next major catalyst just days away — Ocugen is scheduled to present at the Stifel Ophthalmology Forum on May 26 — the coming weeks will test whether pipeline momentum can reclaim the narrative from financing fears.
Ad
Ocugen Stock: Buy or Sell?! New Ocugen Analysis from May 16 delivers the answer:
The latest Ocugen figures speak for themselves: Urgent action needed for Ocugen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 16.
Ocugen: Buy or sell? Read more here...
